<DOC>
	<DOCNO>NCT01476696</DOCNO>
	<brief_summary>The purpose study determine correct prasugrel dosage give child sickle cell disease ( SCD ) .</brief_summary>
	<brief_title>A Study Prasugrel Pediatric Participants With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Are male female SCD [ ( homozygous sickle cell ( HbSS ) hemoglobin S beta ^0 thalassemia ( HbS β^0 thalassemia ) ] Have body weight ≥12 kilogram ( kg ) ≥2 &lt; 18 year age time screen If participant ≥2 ≤16 year age , transcranial Doppler within last year Participants hydroxyurea must stable dose 60 day prior enrollment without sign hematologic toxicity screen Have legal representative competent mental condition provide write informed consent behalf study participant enter study . The child may require give documented assent , require local regulation . If sexually active , negative pregnancy test screening ( female ) agree use reliable method birth control study ( male female ) Known hemoglobin C sickle cell ( HbSC ) hemoglobin S beta ^plus thalassemia ( HbS β^+ thalassemia ) genotypes Vasoocclusive crisis ( VOC ) require medical attention within 15 day prior screen Have concomitant medical illness ( example , terminal malignancy ) opinion investigator associate reduce survival Hepatic dysfunction characterize alanine aminotransferase ( ALT ) ≥ 3 time upper limit normal ( ULN ) Renal dysfunction require chronic dialysis creatinine ≥ 1.5 milligram per deciliter ( mg/dL ) Contraindication antiplatelet therapy History intolerance allergy approve thienopyridines ( clopidogrel , ticlopidine , prasugrel ) Participants hematocrit &lt; 18 % History abnormal conditional transcranial Doppler [ velocity middle cerebral carotid artery ≥170 centimeter per second ( cm/sec ) ] within last year Any history bleed diathesis Any history renal papillary necrosis Active internal bleeding History spontaneous gastrointestinal bleeding Gross hematuria &gt; 300 red blood cell ( RBC ) /highpowered field ( HPF ) urinalysis time screen Any history vitreous hemorrhage Prior history hemorrhagic ischemic stroke , transient ischemic attack ( TIA ) , intracranial hemorrhage Have clinical finding , judgment investigator , associate increase risk bleed Platelet count &lt; 100,000 per microliter ( μl ) blood Have recent surgery ( within 30 day prior screen ) schedule undergo surgery within next 60 day History dysfunctional uteral bleeding , judgment investigator Treatment pack RBC whole blood transfusion therapy within 30 day prior dose Any nonsteroidal antiinflammatory drug ( NSAID ) use within 5 day prior screen Any aspirin , warfarin , thienopyridine , antiplatelet medication use within 10 day prior dose Anticipated use aspirin , warfarin , thienopyridine , antiplatelet medication study period</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Sickle cell disease</keyword>
	<keyword>pediatrics</keyword>
	<keyword>SCD</keyword>
	<keyword>child</keyword>
	<keyword>child</keyword>
	<keyword>kid</keyword>
	<keyword>pain crisis</keyword>
	<keyword>sickle cell anemia</keyword>
	<keyword>sickle cell pain</keyword>
</DOC>